| Drug General Information |
| Drug ID |
D09XCX
|
| Former ID |
DNC014615
|
| Drug Name |
PIRINIXIC ACID
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H14ClN3O2S
|
| InChI |
InChI=1S/C14H14ClN3O2S/c1-8-4-3-5-10(9(8)2)16-12-6-11(15)17-14(18-12)21-7-13(19)20/h3-6H,7H2,1-2H3,(H,19,20)(H,16,17,18)
|
| InChIKey |
SZRPDCCEHVWOJX-UHFFFAOYSA-N
|
| CAS Number |
CAS 50892-23-4
|
| PubChem Compound ID |
|
| PubChem Substance ID |
454960, 4254149, 5455853, 7980894, 8141096, 8147703, 8153490, 10320072, 11114026, 11120023, 11120511, 11120999, 11121605, 11122085, 11147106, 11362674, 11364765, 11365236, 11367327, 11367798, 11369889, 11370619, 11370620, 11372929, 11373399, 11375489, 11375960, 11378054, 11407059, 11459192, 11460910, 12015627, 14874874, 17396608, 24892928, 26612744, 26652899, 26747165, 26752163, 26752164, 26752165, 26752166, 26759758, 29224731, 47662011, 47959463, 47959464, 48034839, 48413425, 48422051
|
| Target and Pathway |
| Target(s) |
Peroxisome proliferator activated receptor alpha |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
cAMP signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Hepatitis C
|
|
Pathway Interaction Database
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Reactome
|
RORA activates gene expression
|
|
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
PPARA activates gene expression
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Transcriptional activation of mitochondrial biogenesis
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathway
|
|
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Circadian Clock
|
|
WikiPathways
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
PPAR Alpha Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
Adipogenesis
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Circadian Clock
|
|
Nuclear Receptors
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2666). |
|---|
| REF 2 | Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90.O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. |
|---|
